<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763125</url>
  </required_header>
  <id_info>
    <org_study_id>EK 366/2003</org_study_id>
    <nct_id>NCT01763125</nct_id>
  </id_info>
  <brief_title>Tumor Bank for Blood Samples</brief_title>
  <official_title>Establishment of a Blood Sample Bank in the Field of Gynaecological Oncology.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy
      people as controls. The blood samples will be collected systematically together with the
      corresponding clinical data. The biological samples, the clinical date together with
      prospective experimental date constitute the entity of the tumor bank.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to
      translational research. The relevance of &quot;translational oncology&quot; will only increase in the
      future -&quot;From bench to bedside&quot; - the swift implementation of new science research results in
      clinical studies in order to expedite progress in clinical cancer therapy for the benefit of
      the patient.

      Its almost a matter of course in the medical science today to collect biological samples
      together with clinical information thereby creating the foundation for future excellent
      fundamental research.

      The aim of this tumor bank is to consist of biological samples (together with a tissue bank -
      see EK 260/2003) and isolates of tumor patients and healthy people as controls. The
      biological samples, the clinical date together with prospective experimental date constitute
      the entity of the tumor bank. The content of the tumor bank can provide essential material
      for current and future research (e.g. analyses of prognostic or predictive tumor markers;
      genetically analysis (polymorphism, mutation, hypermethylation; verification and
      characterisation of disseminated tumor cells).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2003</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.</measure>
    <time_frame>14 years</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Neoplasms of the Female Genitalia</condition>
  <condition>Lung Neoplasms</condition>
  <condition>Endocrine Gland Neoplasms</condition>
  <arm_group>
    <arm_group_label>Malignant tumors</arm_group_label>
    <description>Patients who have one of the Neoplasms stated above under &quot;conditions&quot;. Blood samples will be taken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign controls</arm_group_label>
    <description>Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.
Blood samples will be taken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
Blood samples will be taken.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood collection</intervention_name>
    <description>Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.</description>
    <arm_group_label>Malignant tumors</arm_group_label>
    <arm_group_label>Benign controls</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Universal tumor bank
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  Male and female patients/people.

          -  Minimum age 18 years

          -  Characteristics: Recruited at the Medical University Vienna or at one of the
             facilities cooperating with the Vienna Med. University
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Female

          -  Age 18 to 90 years max.

          -  Just one current known malignant disease or

          -  Just one current inflammatory disease

        Exclusion Criteria:

          -  Inflammatory disease and malignant disease

          -  multiple malignancies

          -  multiple diseases

          -  underage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeillinger, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna, Dptm. of Obstetrics &amp; Gynaecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Zeillinger, Prof. Dr.</last_name>
    <phone>+43140400</phone>
    <phone_ext>7831</phone_ext>
    <email>robert.zeillinger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Pecha</last_name>
    <phone>+43140400</phone>
    <phone_ext>2784</phone_ext>
    <email>nina.pecha@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Innsbruck Medical University</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Concin, Prof.Dr.</last_name>
      <phone>+43 50-504-0</phone>
      <email>nicole.concin@i-med.ac.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven - Department of Obstetrics and Gynaecology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace Vergote, Prof.Dr.</last_name>
      <phone>+32/1634</phone>
      <phone_ext>4208</phone_ext>
      <email>ignace.vergote@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Joke de Roover</last_name>
      <phone>+32 16 34</phone>
      <phone_ext>74 19</phone_ext>
      <email>joke.deroover@uz.kuleuven.ac.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol, Charles University, Dpt of Obstet. &amp; Gynaec.</name>
      <address>
        <city>Praha</city>
        <zip>5 15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité University - Campus Virchow Chlinic</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalid Sehouli, Prof.Dr.</last_name>
      <email>Jalid.Sehouli@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Ioana Braicu, Dr.</last_name>
      <phone>+49 30 450 564</phone>
      <phone_ext>002</phone_ext>
      <email>ioana@braicu.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Hasenburg, Prof. Dr.</last_name>
      <phone>+49 761 270</phone>
      <phone_ext>29440</phone_ext>
      <email>annette.hasenburg@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Michaela Bossart, Dr.</last_name>
      <phone>+49 761 270</phone>
      <phone_ext>30250</phone_ext>
      <email>michaela.bossart@uniklinik-freiburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Clinic of Ruhr University Bochum</name>
      <address>
        <city>Herne</city>
        <zip>44626</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens B Tempfer, Prof.Dr.PhD.</last_name>
      <email>clemens.tempfer@marienhospital-herne.de</email>
    </contact>
    <contact_backup>
      <last_name>Günther Rezniczek, Dr.</last_name>
      <phone>+49 2323 499</phone>
      <phone_ext>1058</phone_ext>
      <email>guenther.rezniczek@rub.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology, Division of Gynecologic Oncology, Unit of Preventive Gynecology</name>
      <address>
        <city>Milan</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Peiretti</last_name>
      <phone>+36 2 57489543</phone>
      <email>michele.peiretti@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College London - Faculty of Medicine, Dpt. of Surgery &amp; Cancer</name>
      <address>
        <city>London</city>
        <zip>SW7 2AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hani Gabra, Prof.Dr.</last_name>
      <phone>+44 (0)20 3313</phone>
      <phone_ext>5828</phone_ext>
      <email>h.gabra@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Blagden, Dr.PhD</last_name>
      <phone>+44 (0)208 383</phone>
      <phone_ext>4661</phone_ext>
      <email>s.blagden@imperial.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008 Feb 1;14(3):710-4. doi: 10.1158/1078-0432.CCR-07-1044.</citation>
    <PMID>18245530</PMID>
  </results_reference>
  <results_reference>
    <citation>Königsberg R, Gneist M, Jahn-Kuch D, Pfeiler G, Hager G, Hudec M, Dittrich C, Zeillinger R. Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett. 2010 Jul 1;293(1):117-23. doi: 10.1016/j.canlet.2010.01.003. Epub 2010 Feb 18.</citation>
    <PMID>20167419</PMID>
  </results_reference>
  <results_reference>
    <citation>Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010 Dec 3;10:666. doi: 10.1186/1471-2407-10-666.</citation>
    <PMID>21129172</PMID>
  </results_reference>
  <results_reference>
    <citation>Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, de Santis M, Zeillinger R, Hudec M, Dittrich C. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Acta Oncol. 2011 Jun;50(5):700-10. doi: 10.3109/0284186X.2010.549151. Epub 2011 Jan 24.</citation>
    <PMID>21261508</PMID>
  </results_reference>
  <results_reference>
    <citation>Obermayr E, Castillo-Tong DC, Pils D, Speiser P, Braicu I, Van Gorp T, Mahner S, Sehouli J, Vergote I, Zeillinger R. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium. Gynecol Oncol. 2013 Jan;128(1):15-21. doi: 10.1016/j.ygyno.2012.09.021. Epub 2012 Sep 24.</citation>
    <PMID>23017820</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Univ.Prof.Dr. Robert Zeillinger</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Endometrium carcinoma</keyword>
  <keyword>Cervix carcinoma,</keyword>
  <keyword>Mamma carcinoma,</keyword>
  <keyword>Prostata carcinoma</keyword>
  <keyword>Colon carcinoma</keyword>
  <keyword>Rectal carcinoma</keyword>
  <keyword>Bronchus carcinoma</keyword>
  <keyword>NSCLC &amp; SCLC (Non Small Cell Lung Cancer &amp; Small Cell Lung Cancer))</keyword>
  <keyword>Prostate carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endocrine Gland Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

